Previous 10 | Next 10 |
AIM ImmunoTech (NYSE:AIM) announces strategic sale of its facility located in New Brunswick, New Jersey for a purchase price of $3.9M. The Company will retain access to space in the New Brunswick facility for activities related to Alferon-N and also intends to lease additi...
OCALA, Fla., March 07, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral...
AIM ImmunoTech (NYSE:AIM) has announced the appointment of Robert Dickey IV, as its Chief Financial Officer. Effective April 4, 2022, Mr. Dickey will become CFO and Ellen Lintal, who has served as the Company’s CFO, will transition to serve as a finance and accounting consultant for AI...
OCALA, Fla., March 03, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral...
AIM ImmunoTech management to participate in webinar Thursday, January 27 th from 2:00 pm - 3:00 pm ET Company to discuss clinical plans for investigational drug Ampligen for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID ...
Chemokine-modulating IP chemo-immunotherapy combination demonstrated to be well tolerated, and associated with interferon stimulated gene changes that favor cytotoxic T lymphocytes chemoattraction and function Strength of data support advancement into Phase 2 clinical study ...
OCALA, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral ...
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 / JTC Team ("JTC"), a fully integrate...
OCALA, Fla., Dec. 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that safety data on its drug Ampligen was recently presented at the Eighth European Scientific Working Group on Influenza (ESWI) virtual conference in Salzburg, Austria, on December 4-7, ...
OCALA, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas Equels, Chief Executive Officer of AIM, will be participating in two upcoming investor conferences. BioFlorida Conference Mr. Equels will be participating in the "...
News, Short Squeeze, Breakout and More Instantly...
OCALA, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of new pre-clinical data concerning the company’s drug Ampligen as part of a combinational therapy in the...
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Pitch Con...
OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series ...